We are live on ! Find out more
GBT

Global Blood Therapeutics, Inc.
GBT

Delisted

GBT was delisted on the 4th of October, 2022.

Back to rankings

2 hedge funds and large institutions have $42.1K invested in Global Blood Therapeutics, Inc. in 2022 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 239 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% less funds holding

Funds holding: 247 → 2 (-245)

100% less funds holding in top 10

Funds holding in top 10: 21 → 0 (-21)

100% less capital invested

Capital invested by funds: $4.73B → $42.1K (-$4.73B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 239

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
2
Holders Change
-245
Holders Change %
-99.19%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
-21
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
239
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$428M
2
BlackRock
BlackRock
New York
-$323M
3
BBA
Baker Bros. Advisors
New York
-$254M
4
PCM
Pentwater Capital Management
Florida
-$218M
5
State Street
State Street
Massachusetts
-$162M
Name Holding Trade Value Shares
Change 		Change in
Stake
PCM
201
PenderFund Capital Management
British Columbia, Canada
– -$318K -3,380 Closed
Simplex Trading
202
Simplex Trading
Illinois
– -$221K -3,250 Closed
TI
203
Telemetry Investments
New York
– -$218K -3,200 Closed
PHK
204
Point72 Hong Kong
Hong Kong
– -$177K -2,595 Closed
Macquarie Group
205
Macquarie Group
Australia
– -$225K -2,527 Closed
SAM
206
Shell Asset Management
Netherlands
– -$151K -2,214 Closed
Lazard Asset Management
207
Lazard Asset Management
New York
– -$123K -1,815 Closed
Allspring Global Investments
208
Allspring Global Investments
North Carolina
– -$64K -940 Closed
Baillie Gifford & Co
209
Baillie Gifford & Co
United Kingdom
– -$61K -892 Closed
CG
210
Cutler Group
California
– -$54K -800 Closed
MTCM
211
Mint Tower Capital Management
Netherlands
– -$54K -790 Closed
SIA
212
SkyView Investment Advisors
New Jersey
– -$52K -766 Closed
CUAMC
213
China Universal Asset Management Company
China
– -$43K -632 Closed
DFCM
214
Dark Forest Capital Management
Puerto Rico
– -$38K -558 Closed
LIM
215
Longfellow Investment Management
Massachusetts
– -$36K -533 Closed
Osaic Holdings
216
Osaic Holdings
Arizona
– -$35K -521 Closed
LSA
217
Leonteq Securities AG
Switzerland
– -$34K -500 Closed
CFGS
218
Concourse Financial Group Securities
Alabama
– -$29K -430 Closed
TC
219
Truvestments Capital
Florida
– -$20K -300 Closed
TWA
220
TCI Wealth Advisors
Arizona
– -$19K -278 Closed
PTC
221
Private Trust Company
Ohio
– -$17K -250 Closed
Daiwa Securities Group
222
Daiwa Securities Group
Japan
– -$15K -214 Closed
CA
223
Crewe Advisors
Utah
– -$13K -191 Closed
LC
224
Lindbrook Capital
California
– -$12K -172 Closed
EBA
225
Eagle Bay Advisors
New York
– -$11K -160 Closed
6 7 8
9
10

GBT Hedge Fund Activity: Q4 2022 in Review

2 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Global Blood Therapeutics, Inc. (GBT) for Q4 2022, worth a combined $42.1K — down 100% from $4.73B a quarter earlier.

Sellers outnumbered buyers: 239 funds closed out of GBT and 0 opened new positions — a net loss of 239 holders — while 1 trimmed existing stakes and 0 added.

The largest seller was Vanguard Group, exiting entirely with an estimated $428M sold.

  • 2 institutional investors held Global Blood Therapeutics, Inc. (GBT) as of Q4 2022, down from 247 in Q3 2022.
  • Funds reported $42.1K of Global Blood Therapeutics, Inc. stock for Q4 2022, down 100% quarter-over-quarter.
  • 0 funds opened new Global Blood Therapeutics, Inc. positions in Q4 2022 and 239 closed out, a net change of -239 holders.
  • The largest Global Blood Therapeutics, Inc. seller in Q4 2022 was Vanguard Group, an estimated $428M sold.

Based on aggregated 13F filings for Q4 2022.